Targeting Adenosine Receptors for the Treatment of Cardiac Fibrosis.

Autor: Vecchio EA; Monash Institute of Pharmaceutical Sciences, Monash University, ParkvilleVIC, Australia.; Department of Pharmacology, Monash University, ParkvilleVIC, Australia., White PJ; Monash Institute of Pharmaceutical Sciences, Monash University, ParkvilleVIC, Australia., May LT; Monash Institute of Pharmaceutical Sciences, Monash University, ParkvilleVIC, Australia.; Department of Pharmacology, Monash University, ParkvilleVIC, Australia.
Jazyk: angličtina
Zdroj: Frontiers in pharmacology [Front Pharmacol] 2017 May 05; Vol. 8, pp. 243. Date of Electronic Publication: 2017 May 05 (Print Publication: 2017).
DOI: 10.3389/fphar.2017.00243
Abstrakt: Adenosine is a ubiquitous molecule with key regulatory and cytoprotective mechanisms at times of metabolic imbalance in the body. Among a plethora of physiological actions, adenosine has an important role in attenuating ischaemia-reperfusion injury and modulating the ensuing fibrosis and tissue remodeling following myocardial damage. Adenosine exerts these actions through interaction with four adenosine G protein-coupled receptors expressed in the heart. The adenosine A 2B receptor (A 2B AR) is the most abundant adenosine receptor (AR) in cardiac fibroblasts and is largely responsible for the influence of adenosine on cardiac fibrosis. In vitro and in vivo studies demonstrate that acute A 2B AR stimulation can decrease fibrosis through the inhibition of fibroblast proliferation and reduction in collagen synthesis. However, in contrast, there is also evidence that chronic A 2B AR antagonism reduces tissue fibrosis. This review explores the opposing pro- and anti-fibrotic activity attributed to the activation of cardiac ARs and investigates the therapeutic potential of targeting ARs for the treatment of cardiac fibrosis.
Databáze: MEDLINE
Externí odkaz: